4561 Background: Metastatic Chromophobe renal cell carcinoma (mChRCC) is a rare entity with no specific targeted therapy recommended. We aim to assess the outcome of targeted therapy (TT) in a large cohort of mChRCC patients (pts). Methods: RCCG collected data from 27 centers in France, UK and Italy. Patients’ characteristics, treatments, best response and outcomes were collected. Time to treatment failure (TTF) for first-line treatment was calculated from the initiation of first-line treatment (t0) until failure (progression disease, toxicity, death). Overall survival (OS [95%CI]) was calculated from t0 until death. Survival outcomes were described using Kaplan-Meier method with 95% confidence interval. Results: Overall, 91 mChRCC pts were collected. Among these, 63 were treated with TT with a median follow-up of 3 years (range: 0.1-14). Median age at diagnosis was 58 years with a majority of men (62%, n = 39). Most pts had nephrectomy (92%, n = 58). International Metastatic RCC Database Consortium (IMDC...